SCHEDULE: Lind Global Fund II Discloses 3.2% Stake in ABVC BioPharma

Lind Global Fund II LP, along with its general partner and managing member, disclosed a 3.2% beneficial ownership stake in ABVC BioPharma, Inc. as of June 30, 2025.

Summary

• Lind Global Fund II LP, Lind Global Partners II LLC, and Jeff Easton (collectively, the 'Reporting Persons') have filed an Amendment No. 4 to Schedule 13G regarding their beneficial ownership in ABVC BioPharma, Inc.
• The Reporting Persons collectively beneficially own 557,143 shares of ABVC BioPharma's common stock, representing 3.2% of the class.
• This ownership consists of 0 shares of common stock, 500,000 B Warrants to purchase common stock, and 57,143 shares of common stock issuable from convertible securities.
• Lind Global Fund II LP, Lind Global Partners II LLC, and Jeff Easton each hold sole voting and dispositive power over these 557,143 shares.
• The address for the Reporting Persons is 444 Madison Ave, Floor 41, New York, NY 10022.

Sentiment

Score: 6

Explanation: The filing is a routine disclosure of beneficial ownership. The presence of an institutional investor holding warrants and convertible securities can be viewed as a mild positive, indicating continued investment interest, though the percentage is not a controlling stake.

Positives

• The continued disclosure of an institutional investor, Lind Global Fund II LP, holding a stake in ABVC BioPharma, Inc. may indicate ongoing investor interest and confidence.
• The beneficial ownership includes warrants and convertible securities, suggesting a structured investment that could provide future capital or flexibility to the company.

Negatives

• The filing itself does not contain explicit negative information; it is a factual disclosure of beneficial ownership.

Risks

• The filing certifies that the securities were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer, nor in connection with any transaction having that purpose or effect, other than activities solely in connection with a nomination under SEC rules.

Future Outlook

The filing is a disclosure of current beneficial ownership and does not provide any forward-looking statements or guidance regarding the issuer's future performance or strategic plans.

Industry Context

This filing is a standard regulatory disclosure of beneficial ownership by an institutional investor in a publicly traded biopharma company. It does not provide specific insights into broader industry trends or competitive landscape, but the involvement of investment funds like Lind Global Fund II is common across various sectors, including biotechnology.

Stakeholder Impact

• Shareholders: The disclosure provides transparency regarding a significant institutional investor's stake, which can influence market perception and liquidity.
• Company Management: Awareness of significant investor holdings is important for investor relations and strategic planning.

Key Dates

Keywords

ABVC BioPharma, Lind Global Fund II, Schedule 13G, Beneficial Ownership, Common Stock, Warrants, Convertible Securities, Institutional Investor, SEC Filing